Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts
Authors' conclusion
This study provides reassuring data on humoral response after COVID-19 infection in patients treated with disease-modifying anti-rheumatic drugs.
Study context
- Population
- Unvaccinated patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA) in 16 hospitals in France (March–September 2021) and healthcare professionals in Toulouse University Hospital (June–July 2020), after SARS-CoV-2 infectionmean age 49 years, 76% females
- Participants
- 95 vs 95
- Comparison
- Unvaccinated RA, SpA or PsA patients after SARS-CoV-2 infection (COVID-RIC-2) vs matched healthcare professionals (COVID-BIOTOUL)
- COVID-RIC-2n = 95
- COVID-BIOTOULn = 95reference
- Outcome
- Total SARS-CoV-2 antibody titres, centrally measured
Methodological detailsmatched by age, sex and time-sampling on infection date, multicentre (16 hospitals in France)
- Matched by age, sex and time-sampling on infection date
- Multicentre (16 hospitals in France)
Main finding
As reported in the abstract
SARS-CoV-2 antibody titres
Observational data: associations, not effects.
Further findings
Antibody titres by COVID-19 severity in COVID-RIC-2
- Trend towards higher antibody titres in patients with severe COVID-19 symptoms
Determinants of antibody titres in COVID-RIC-2
- No impact of age, sex, time-sampling or underlying disease on antibody titres
- Patients taking GC, abatacept or RTX trended toward lower antibody titres
Original publication
Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts. Clin Exp Rheumatol. Published 27 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →